Abbreviations used in this issue AFI = acute febrile illness AMI = acute myocardial infarction AMR = antimicrobial resistance CI = confidence interval EGFR = epidermal growth factor receptor GAS = group A streptococcal HER2 = human epidermal growth factor receptor type 2 hs-cTnI = high-sensitivity cardiac troponin I mCRC = metastatic colorectal cancer NAAT = nucleic acid amplification testing PCR = polymerase chain reaction PlGF = placental growth factor sFlt-1 = soluble fms-like tyrosine kinase 1 Research Review is ten!! The first ever issues of Research Review were delivered to inboxes in February 2006. Fast forward ten years and we now publish 48 regular reviews to which there are over 160,000 subscriptions. We're grateful to each and every one of you for your support and are looking forward to even bigger and better things over the coming years. We hope you find this issue interesting and look forward to hearing your comments.
Reliability of point-of-care capillary blood glucose measurements in the critical value range Authors: Schifman RB, et al.
Summary:
The reliability of point-of-care (POC) capillary blood glucose measurements was evaluated in the critical high (>600 mg/dL) and low (<40 mg/dL) ranges in this one-year retrospective analysis of results from routine patient care. Re-testing following non-critical POC capillary blood glucose results was also performed on a sample of venous blood specimens using a different POC device. The overall rate of critical values was 2.4 per 1000 POC glucose tests (256 of 105,928; 0.24%); emergency department tests produced the highest rate (3.32%). Critical high values were twice as frequent as critical low values. Repeat testing was performed in nearly 80% of cases of critical results within 10 minutes. Of these repeat tests, 54.9% met accuracy criteria (±15 mg/dL of low and ±20% of high initial values). Significantly higher accuracy was observed when the same operator performed retesting with the same meter. There was no significant difference in non-critical results from capillary and venous blood samples (89.8% met accuracy criteria).
Comment (VB):
Given that POC glucose is an extremely common POC test, little is published on the subject, particularly performance within the critical low and high ranges, as noted by the authors. Retrospective analyses make it difficult to ensure consistency in practices, which was evident in this instance, with repeat testing being performed by three different methodologies. Nevertheless, of over 100,000 POC glucose results reviewed in a 12-month period, only 256 were within the study critical range values and only 80% of these were repeated, although of those that were only 40% and 63% of low and high values respectively were repeatable. This highlights that there should be very clear guidelines for, and awareness among, non-laboratory staff around critical values that require confirmation, as potential inaccuracies in the critical range due to preanalytic factors can impact on patient treatment. A policy around this has been implemented at the authors' laboratory, which is commendable.
Vanessa Buchan, Quality Manager, Canterbury Health Laboratories.
Reference : Arch Pathol Lab Med. 2014 Jul; 138(7):962-6 . Abstract Melanoma prognostics and personalized therapeutics at a crossroad Author: Lo RS. Summary: The author of this paper provided a commentary on novel targeted therapies and immunotherapies for melanoma, including BRAF and immune checkpoint inhibitors. It is highly anticipated that use of these agents in the adjuvant setting may be able to improve survival in patients diagnosed with earlier stage disease but at high risk for relapse post surgery. Predictive biomarkers for responses to therapy such as BRAF V600 mutations, and potentially melanoma-associated immunity, may also double as prognostic biomarkers for high-risk stage III patients and may thus enable patient stratification in relation to the application of novel adjuvant therapies.
Comment (JG):
The main purpose of this article is to introduce the concept of the use of targeted therapy and tumour-associated checkpoint inhibitors for patients with earlier stage melanoma but who are at high risk for metastatic disease. In this regard, melanoma is likened to breast cancer, where Herceptin was only used initially for advanced breast cancer but in time became the standard of care for early breast cancer patients. In this brief commentary, melanoma is discussed as a so-called "poster child", using game-changing targeted therapies and immunotherapies. Over the past 3 years, there have been unprecedented, albeit short-lived, responses to treatment in advanced melanoma. These have given cause for real hope for patients for the first time ever! The concepts of inhibition of oncogenic driver mutations such as BRAF and of tumour-associated immunity are briefly discussed. The most wellknown drug inhibiting mutant BRAF, vemurafenib, and the first immune checkpoint inhibitor developed against T-lymphocytes, ipilimumab, are used as examples. Both have been approved for use in New Zealand but are not funded by Pharmac. Two further checkpoint inhibitors called PD1 and PDL1 are also discussed. These are the subject of much recent excitement as they are in phase 3 international clinical trials with outstanding preliminary results in advanced melanoma. Some of our Canterbury patients have been enrolled in these more recent trials. These drugs are also showing promise in the treatment of non-small cell carcinoma of the lung. In the laboratory, melanoma cells can be tested for a range of prognostic and predictive biomarkers in order to select patients for treatment and/or trial inclusion. A prognostic factor offers information on the likely course of a cancer without treatment and a predictive factor offers information to stratify subsets of patients who are more likely to respond to therapy. Stratification of high-risk melanoma patients at presentation on the basis of prognostic biomarkers that are linked to therapeutic biomarkers may identify those most receptive to adjuvant BRAF and/or immune checkpoint inhibitors. 
Summary:
The authors prospectively evaluated the prognostic value of gene-expression assays in 10,253 women with hormone-receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, axillary node-negative breast cancer with tumours of 1.1-5.0 cm in the greatest dimension (or 0.6-1.0 cm in the greatest dimension and intermediate-or high-tumour grade) who met established guidelines for the consideration of adjuvant chemotherapy on the basis of clinicopathologic features. Using a reversetranscriptase PCR assay of 21 genes on paraffin-embedded tumour tissue, a risk of breast cancer recurrence score was calculated. On a scale of 0-100, a recurrence score of 0-10 was considered indicative of a very low risk of recurrence. A total of 1626 women (15.9%) with a recurrence score in this range were assigned to receive endocrine therapy without chemotherapy. At 5 years, these patients had a rate of invasive disease-free survival of 93.8% (95% CI 92.4-94.9), a rate of freedom from recurrence of breast cancer at a distant site of 99.3% (95% CI 98.7-99.6), a rate of freedom from recurrence of breast cancer at a distant or local-regional site of 98.7% (95% CI 97.9-99.2) and a rate of overall survival of 98.0% (95% CI 97.1-98.6).
Comment: This substantial 5-year study followed a cohort of women with hormonereceptor-positive, HER2-negative, axillary node-negative breast cancers treated only with endocrine therapy. The women included in the study had a low risk of recurrence (0-10 score) as judged by a 21 gene reverse-transcriptase PCR panel (Oncotype DX) and thus were treated with endocrine therapy alone without chemotherapy. Recurrence events were uncommon regardless of histologic grade and were not significantly affected by younger age at diagnosis. This prospectively conducted study supports the use of the 21-gene assay to spare the use of chemotherapy in patients who otherwise would be recommended to receive it on the basis of clinicopathologic features.
Reference: N Engl J Med. 2015;373(21):2005-14. Abstract
A comparative study between smartphonebased microscopy and conventional light microscopy in 1021 dermatopathology specimens Authors: Jahan-Tigh RR, et al.
Summary:
This prospective, blinded study assessed the diagnostic performance of a simple smartphone microscope constructed with a 3 mm ball lens by evaluating 1021 referred, consecutive dermatopathology specimens from the community at a single university hospital. Compared to conventional light microscopy, the performance characteristics of the smartphone platform were calculated for the diagnosis of melanoma, non-melanoma skin cancers, and other miscellaneous conditions. The sensitivity and specificity of smartphone microscopy for basal cell carcinoma (n=136) were 95.6% and 98.1%, respectively, and for squamous cell carcinoma (n=94) were 89.4% and 97.3%, respectively. The lowest sensitivity (60%) was reported for melanoma (n=15), although specificity was high (99.1%). Variable diagnostic accuracy was reported for inflammatory conditions and other neoplasms.
Comment: This rather unimpressive paper compared the performance of a light microscope to that of a smartphone with a ball lens attached via double-sided tape in the diagnosis of dermatopathology specimens. It produced a new discipline in laboratory medicine: the "smartphone microscopist". Figures 1-3 showed the setup and comparative view of a nodular basal cell carcinoma, which through the smartphone camera lens looked indistinct and foggy. It is not surprising then that the study of 1021 specimens showed poor performance for melanomas, fungal and inflammatory conditions. Among the more alarming discrepant results was a melanoma that the smartphone microscopist called a solar lentigo and two squamous cell carcinomas that were mistaken for a melanoma and a verucca, respectively, by the phone lens. Whilst the authors assert that mobile tele-dermatology can bring much needed expertise to resource poor healthcare settings, I think the technology is better used for objective tests such as PCR or biochemical measurements as has been shown in previous studies.
Reference : Arch Pathol Lab Med. 2016; 140(1):86-90 . Abstract Development of a TaqMan array card for acute-febrile-illness outbreak investigation and surveillance of emerging pathogens, including Ebola virus Authors: Liu J, et al.
The aetiologic agent in acute febrile illness (AFI) often remains unidentified. The authors of this study assessed a real-time PCR-based TaqMan array card able to yield test results for six to eight samples within 2.5 h and simultaneously detect 26 AFI-associated organisms, including 15 viruses, eight bacteria and three protozoa. In order to ensure extraction and amplification efficiency, two extrinsic controls (phocine herpesvirus 1 and bacteriophage MS2) were included. Analytical validation was performed on spiked specimens for linearity, intra-assay precision, inter-assay precision, limit of detection, and specificity. A total of 1,050 clinical blood samples were tested. Compared to individual real-time PCR assays, the TaqMan array card demonstrated an overall sensitivity of 88% (278/315; 95% CI 84-92%) and specificity of 99% (5,261/5,326; 95% CI 98-99%).
Comment: The slow recognition of Ebola in Guinea was largely due to delays in laboratory diagnosis and the inability to perform molecular testing in the region. This paper details the extensive development of a multiplex TaqMan array card (Life Technologies) for real-time PCR detection of 15 viruses (Ebola, Marburg, West Nile, Yellow fever etc.), eight bacteria (Bartonella spp., Brucella spp., Leptospira spp., Salmonella spp., etc.) and three protozoa (Plasmodium etc.) that cause AFI in Africa. Using spiked as well as clinical specimens, the card had an overall sensitivity of 88% and 99% specificity compared to individual realtime PCR assays, although high burden infections such as Ebola showed 100% sensitivity and specificity. Given that there may be multiple agents contributing to fever (45% of Ebola-infected samples were co-infected with Plasmodium), this card is efficient and with its ability to test six to eight samples within 2.5 h will be a useful tool for its intended use in outbreak investigation and AFI surveillance in Africa. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients Authors: Liang DH, et al.
Reference

Summary:
The authors performed a retrospective chart review of 100 patients with stage 4 or high-risk stage 3 breast cancer to assess genomic sequencing of cell-free DNA compared with that of tumour DNA for monitoring disease progression and response to therapy. TP53 and PIK3CA mutations and EGFR and ERBB2 amplification were the most common genomic alterations. Robust agreement between tumour DNA and cell-free DNA (Cohen's kappa = 0.64 and 0.77, respectively) was reported for PIK3CA mutation and ERBB2 amplification; poor agreement (Cohen's kappa = 0.18 and 0.33, respectively) was reported for TP53 mutation and EGFR amplification. A significant association between directional changes of TP53 and PIK3CA mutant allele frequency and response to therapy was demonstrated (p=0.002). Presence of TP53 mutation (p=0.0004) and PIK3CA mutant allele frequency (p=0.01, HR 1.074 [95 % CI 1.018-1.134]) were significant predictors of progression-free survival.
Comment: This retrospective study of 100 stage 4 or high-risk stage 3 breast cancer cases attempted to identify selected cancer-specific genomic alterations from cell-free DNA as indicators of disease progression and opportunities for targeted therapy. The promise of a simple blood test to monitor breast cancer progression is attractive. However, these data are complicated to assess because of the small sample size, lack of consistency between sample collection time points and diversity of cancer specific mutations being screened for by several different companies over time. The authors conclude that due to an imperfect agreement between tumour DNA genomic alternations and those found in cell-free DNA, the latter is unlikely to replace the need for tumour DNA analysis and traditional imaging studies. More work is needed.
Reference: Breast Cancer Res Treat. 2016;155(1):139-49. Abstract
Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion update 2015
Authors: Allegra CJ, et al.
Summary:
This American Society of Clinical Oncology Provisional Clinical Opinion update gives recommendations on the use of extended RAS gene mutation testing in patients with metastatic colorectal cancer (mCRC) to detect resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapy. Patients with mCRC tumours harbouring RAS mutations in exons 2 (codons 12 and 13), 3 (codons 59 and 61), and 4 (codons 117 and 146) have been found to be unlikely to benefit from EGFR antibody therapy as monotherapy or combined with chemotherapy in recent phase II and III clinical trials. Additional recent data from 11 systematic reviews with meta-analyses, two retrospective analyses, and two health technology assessments based on a systematic review include outcomes in patients with mCRC and the presence or absence of mutation in additional exons in KRAS and NRAS. The weight of current evidence indicates that anti-EGFR antibody therapy should only be considered in patients without detected mutations after such extended RAS testing. Thus, it is recommended that all patients with mCRC who are candidates for anti-EGFR antibody therapy should have their tumour tested in a Clinical Laboratory Improvement Amendments-certified laboratory for mutations in both KRAS and NRAS exons 2 (codons 12 and 13), 3 (codons 59 and 61), and 4 (codons 117 and 146).
Comment: As a result of their assessment of 11 systematic reviews with meta-analyses, two retrospective analyses and two health technology assessments, ASCO now recommends that before treatment with anti-EGFR antibody therapy, patients with mCRC should have their tumour tested for mutations in KRAS exon 2 (codons 12 and 13) AND:
• KRAS exons 3 (codons 59 and 61) and 4 (codons 117 and 146) • NRAS exons 2 (codons 12 and 13), 3 (codons 59 and 61), and 4 (codons 117 and 146) This is an interesting extension to testing as mutations in NRAS comprise a small proportion of patients with mCRC (approx. 2%). While RAS gene mutations predict that patients may have worse outcomes from the addition of either cetuximab or panitumumab to chemotherapy, the failure to detect RAS mutations does not guarantee that a patient will benefit. Therefore other biomarkers are needed to determine the best treatment for patients with mCRC because the efficacy of anti-EGFR antibody therapy, even in the RAS wild-type population, is modest.
Reference: J Clin Oncol. 2016; 34(2):179-85 . Abstract DNA yield from tissue samples in surgical pathology and minimum tissue requirements for molecular testing Authors: Austin MC, et al.
This study sought to assess tissue adequacy to yield enough DNA for complex molecular assays. Slide-based measurements were used to investigate the relationship between processed tissue volume and DNA yield by A260 from 366 formalinfixed, paraffin-embedded tissue samples submitted for EGFR, KRAS, and BRAF testing. All samples with a volume >8 mm 3 yielded at least 1 μg of DNA; over 80% of samples providing less than 1 μg of DNA were less than 4 mm 3 in volume. Tissue samples of 9 mm 3 are expected to yield >1 μg of DNA 99% of the time.
Comment: This very useful paper offers practical advice on how low you can go with the volume of formalin-fixed, paraffin-embedded tissue before you don't have enough DNA for common adjunct molecular testing for KRAS, EGFR and BRAF. A DNA yield of 1.0 μg or greater was obtained from 90% of the tissue samples with a volume of 4 mm 3 or greater and 100% of tissue samples with volume 8 mm 3 or greater. The authors suggest that this translates to a minimum of two 1 cm cores from an 18-gauge needle.
Reference: Arch Pathol Lab Med. 2016;140(2):130-3. Abstract
Privacy Policy: Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time. Disclaimer: This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits. Summary: A prospective study was performed to develop a 2-h algorithm for rule-out and rule-in of acute myocardial infarction (AMI) using high-sensitivity cardiac troponin I (hs-cTnI) values in a derivation cohort of 1435 patients and an external validation cohort of 1194 patients with suspected AMI presenting to the emergency department. Blinded measurements of hs-cTnI were performed at presentation and after 2 h. Two independent cardiologists adjudicated the final diagnosis. A final diagnosis of AMI was made in 17% and 13% in the derivation and validation cohorts, respectively. In the derivation cohort, 56% of patients were classified as rule-out, 17% as rule-in, and 27% as observation according to the 2-h algorithm developed. Diagnostic sensitivity was 99.2% and negative predictive value was 99.8% for rule-out; specificity and positive predictive value were 95.2% and 75.8%, respectively, for rule-in. In the validation cohort, 60% of patients were classified as rule-out, 13% as rule-in, and 27% as observation. Diagnostic sensitivity was 98.7% and negative predictive value was 99.7% for rule-out; specificity and positive predictive value were 97.4% and 82.2%, respectively, for rule-in. In both cohorts, 100% of rule-out patients were alive at 30 days.
Comment: This prospective study sought to develop a 2-h algorithm for use of hs-cTnI in the early triage of patients with possible AMI. Testing was conducted on the Architect STAT high-sensitivity troponin I (Abbott Laboratories) on serum collected at presentation to Accident & Emergency and again after 2 h. Rule-out criteria were defined as a maximal hs-cTnI concentration within the first 2 h of <6 ng/L and an absolute change within the first 2h of <2 ng/L. For rule-in of AMI the optimal thresholds were either a maximal hs-cTnI value within the first 2 h of ≥64 ng/L or an absolute change in hs-cTnI within the first 2 h of ≥15 ng/L. One limitation is that the patients in this study were in the Accident & Emergency and further studies are required to quantify the performance of this algorithm in patients with lower (Primary Care) or higher (e.g. Coronary Care Unit setting) pre-test probability.
Reference : Clin Chem. 2016; 62(3):494-504. Abstract Epidemiological typing of Neisseria gonorrhoeae and detection of markers associated with antimicrobial resistance directly from urine samples using next generation sequencing Authors: Graham RM, et al.
Summary:
This study assessed next generation sequencing of Neisseria gonorrhoeae from clinical specimens for generating information on epidemiological genotyping and antimicrobial resistance (AMR) markers. DNA was extracted, enriched for microbial DNA and sequenced from 13 urine specimens testing positive for N. gonorrhoeae by nucleic acid amplification testing (NAAT). After filtering out sequences aligned to the human genome, the remaining sequences were de novo assembled and the resulting contigs searched for regions of interest. MLST and NG-MAST alleles were assigned according to the schemes at PubMLST.org and NG-MAST.net, respectively. A sufficient number of N. gonorrhoeae sequence reads were obtained from 11 of the 13 samples in order to provide full coverage of the genome at a depth of 6-130×. Each of these samples yielded complete MLST and NG-MAST sequence types. In searching for 10 different AMR markers in genes associated with reduced susceptibility to several antimicrobials, both previously reported and novel mutations were identified.
Comment: Whilst the wily gonococcus continues to cause alarm with its ever-increasing levels of AMR, the shift to diagnosis of gonorrhoea by NAAT has unfortunately limited the availability of isolates for epidemiological typing and phenotypic antimicrobial susceptibility testing. This small study offers the exciting alternative of sequencing the entire genome of N. gonorrhoeae directly from clinical samples using next generation sequencing. Using total DNA isolated from 13 urine-Cobas PCR media (Roche) specimens (positive for N. gonorrhoeae using the Roche Cobas 4800 CT/NG test), this study showed that 11 of the samples generated a sufficient number of sequence reads to provide complete MLST and NG-MAST sequence types as well as 10 different AMR markers. Enrichment of the DNA samples for microbial sequences was essential.
Whilst not yet cost-effective, this approach does demonstrate a means to produce valuable epidemiological typing and antimicrobial sensitivity testing directly on clinical NAAT samples. : Sex Transm Infect. 2016 Mar 11. pii: sextrans-2015 . Abstract Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia.
Reference
Authors: Zeisler H, et al.
Summary:
The authors undertook a prospective, multicentre, observational study to derive and validate a soluble fms-like tyrosine kinase 1 (sFlt-1):placental growth factor (PlGF) ratio that would predict the absence or presence of preeclampsia in the short term in women with singleton pregnancies in whom preeclampsia was suspected (24 weeks 0 days to 36 weeks 6 days of gestation). Low sFlt-1:PlGF ratios at or below a derived cut-off were assessed to predict the absence of preeclampsia within 1 week after the first visit and high ratios above the cut-off were assessed to predict the presence of preeclampsia within 4 weeks. An sFlt-1:PlGF ratio cut-off of 38 was identified as having important predictive value in a development cohort of 500 women. In a further 550 women comprising a subsequent validation cohort, an sFlt-1:PlGF ratio ≤38 had a negative predictive value for no preeclampsia in the subsequent week of 99.3% (95% CI 97.9-99.9) with 80.0% sensitivity (95% CI 51.9-95.7) and 78.3% specificity (95% CI 74.6-81.7); an sFlt-1:PlGF ratio >38 had a positive predictive value for a diagnosis of preeclampsia within 4 weeks of 36.7% (95% CI 28.4-45.7), with 66.2% sensitivity (95% CI 54.0-77.0) and 83.1% specificity (95% CI 79.4-86.3).
Comment: This study by Zeisler et al was performed on a subset of women from the larger Roche Diagnostics PROGNOSIS (Prediction of Short-Term Outcome in Pregnant Women with Suspected Preeclampsia Study) prospective observational study. The objective was to derive and validate a cut-off point for the ratio of soluble sFlt-1 to PlGF as a predictor of preeclampsia. An sFlt-1:PlGF ratio of 38 or lower on the Elecsys immunoassays platform (Roche) was predictive of the ABSENCE of foetal adverse outcomes within 1 week (negative predictive value >99%). However, the positive predictive value of a ratio >38 for development of preeclampsia was only 36.7%, but this was considered an improvement on the predictive value of proteinuria and blood pressure (~20%). This test may be a useful tool to reduce unnecessary hospitalisations without detriment to foetal and maternal outcomes.
